Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
11 hedge funds and large institutions have $2.23M invested in Evoke Pharma in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
32% less capital invested
Capital invested by funds: $3.29M → $2.23M (-$1.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$164K |
| 2 |
Barclays
London,
United Kingdom
|
+$2.9K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$2.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.93K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sophrosyne Capital
New York
|
-$397K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$174K |
| 3 |
Morgan Stanley
New York
|
-$4K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$2.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $1.47M | +$164K | +170 | +10% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $267K | +$1.93K | +2 | +0.6% |
|
|
CWG
3
C WorldWide Group
Copenhagen,
Denmark
| $250K | +$302K | +313 | New |
|
|
LP
4
LMR Partners
London,
United Kingdom
| $131K | – | – | – |
|
5
Geode Capital Management
Boston,
Massachusetts
| $56K | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $42K | -$174K | -180 | -77% |
|
|
BIM
7
BlackRock Investment Management
Wilmington,
Delaware
| $3K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $3K | +$1.93K | +2 | +200% |
|
|
GSC
9
Ground Swell Capital
Folly Beach,
South Carolina
| $3K | +$2.9K | +3 | New |
|
|
10
Barclays
London,
United Kingdom
| $2K | +$2.9K | +3 | New |
|
|
U
11
UBS
Zurich,
Switzerland
| $1K | -$2.9K | -3 | -60% |
|
|
SC
12
Sophrosyne Capital
New York
| – | -$397K | -340 | Closed |
|
|
13
Morgan Stanley
New York
| – | -$4K | -3 | Closed |
|
EVOK Hedge Fund Activity: Q3 2014 in Review
11 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2014, worth a combined $2.23M — down 32% from $3.29M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVOK positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Opaleye Management, adding an estimated $164K. The largest seller was Sophrosyne Capital, exiting entirely with an estimated $397K sold.
- 11 institutional investors held Evoke Pharma (EVOK) as of Q3 2014, up from 10 in Q2 2014.
- Funds reported $2.23M of Evoke Pharma stock for Q3 2014, down 32% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q3 2014 and 2 closed out, a net change of +1 holder.
- The largest Evoke Pharma buyer in Q3 2014 was Opaleye Management, an estimated $164K added.
- The largest Evoke Pharma seller in Q3 2014 was Sophrosyne Capital, an estimated $397K sold.
Based on aggregated 13F filings for Q3 2014.